ArticleScientific reports2013
Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 79 citations in OpenAlex.
- Membrane-Traversing Peptides: Mechanistic Landscapes, Assays, and Applications.Chemical reviews · 2026Review
- An aegerolysin-like protein from Heliothis virescens ascovirus 3h (HvAV-3h) shows immune suppression and antibacterial activity.The Journal of general virology · 2025Article
- Article
- Shining New Light on Biological Systems: Luminescent Transition Metal Complexes for Bioimaging and Biosensing Applications.Chemical reviews · 2024Review
- Article
- Peptide nanostructures-based delivery of DNA nanomaterial therapeutics for regulating gene expression.Molecular therapy. Nucleic acids · 2023Article
- Macroscopic Fluorescence Lifetime Imaging for Monitoring of Drug-Target Engagement.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.Biomolecules · 2021Review
- Cell-penetrating peptide-mediated cell entry of H5N1 highly pathogenic avian influenza virus.Scientific reports · 2020Article
- Activatable cell-penetrating peptides: 15 years of research.RSC chemical biology · 2020Review
- Advances in oligonucleotide drug delivery.Nature reviews. Drug discovery · 2020Review
- Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury.Drug delivery and translational research · 2020Article
- The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.Theranostics · 2020Review
- Antibody Structure and Function: The Basis for Engineering Therapeutics.Antibodies (Basel, Switzerland) · 2019Review
- Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells.Biomolecules · 2019Article
- Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis.International journal of molecular sciences · 2019Review
- Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines.Scientific reports · 2019Article
- Intracellular oligonucleotide delivery using the cell penetrating peptide Xentry.Scientific reports · 2018Article
- mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446.PloS one · 2018Article
- Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem.Biomolecular concepts · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we describe an entirely new class of cell-penetrating peptide (CPP) represented by the short peptide Xentry (LCLRPVG) derived from an N-terminal region of the X-protein of the hepatitis B virus. Xentry permeates adherent cells using syndecan-4 as a portal for entry, and is uniquely restricted from entering syndecan-deficient, non-adherent cells, such as resting blood cells. Intravenous injection of Xentry alone or conjugated to β-galactosidase led to its delivery to most tissues in mice, except circulating blood cells. There was a predilection for uptake by epithelia. Anti-B-raf antibodies and siRNAs linked to Xentry were capable of killing B-raf-dependent melanoma cells. Xentry represents a new class of CPP with properties that are potentially advantageous for life science and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.